Q32 Bio
QTTB
59 hedge funds and large institutions have $15.9M invested in Q32 Bio in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 10 closing their positions.
4,000% more call options, than puts
Call options by funds: $41K | Put options by funds: $1K
0.15% less ownership
Funds ownership: 1.87% → 1.72% (-0.15%)
5% less funds holding
Funds holding: 62 → 59 (-3)
21% less capital invested
Capital invested by funds: $20M → $15.9M (-$4.13M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$31.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$10.8K |
| 3 |
Squarepoint
New York
|
+$10.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.68K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$411K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$204K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$183K |
| 4 |
Morgan Stanley
New York
|
-$145K |
| 5 |
BlackRock
New York
|
-$96.2K |
QTTB Hedge Fund Activity: Q2 2023 in Review
59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2023, worth a combined $15.9M — down 21% from $20M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of QTTB and 7 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 6 added.
The largest buyer was Assenagon Asset Management, adding an estimated $31.7K. The largest seller was JP Morgan Chase, cutting an estimated $411K.
- 59 institutional investors held Q32 Bio (QTTB) as of Q2 2023, down from 62 in Q1 2023.
- Funds reported $15.9M of Q32 Bio stock for Q2 2023, down 21% quarter-over-quarter.
- 7 funds opened new Q32 Bio positions in Q2 2023 and 10 closed out, a net change of -3 holders.
- The largest Q32 Bio buyer in Q2 2023 was Assenagon Asset Management, an estimated $31.7K added.
- The largest Q32 Bio seller in Q2 2023 was JP Morgan Chase, an estimated $411K sold.
Based on aggregated 13F filings for Q2 2023.